Amphastar Pharmaceuticals AMPH Interest Expense
Interest Expense at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's interest expense?
- Amphastar Pharmaceuticals (AMPH) reported interest expense of $6.55M in Q1 2026.
- How has Amphastar Pharmaceuticals's interest expense changed year-over-year?
- Amphastar Pharmaceuticals's interest expense increased by 4.2% year-over-year, from $6.29M to $6.55M.
- What is the long-term trend for Amphastar Pharmaceuticals's interest expense?
- Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's interest expense has grown at a 131.6% compound annual growth rate (CAGR), from $885K to $25.48M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.